Parkinson Disease

Showing 1–12 of 29 results

EREPORT

Pathophysiology, Patient Burden, and Recognition of OFF Episodes of Parkinson Disease

Do you talk with your patients with Parkinson disease about the burden of OFF episodes? Using assessment tools can spur communication. In this CME activity, follow along as 2 experts review the occurrence and identification of OFF time.

Rajesh Pahwa and Stuart H. Isaacson

EDUCATIONAL ACTIVITY

Effective Treatment Strategies for Motor and Nonmotor Symptoms of Parkinson Disease

Which medications can improve the various motor and nonmotor symptoms of Parkinson disease? Dr Isaacson offers strategies to address multiple challenges posed by the illness.

Stuart H. Isaacson

EDUCATIONAL ACTIVITY

Early Recognition and Diagnosis of Parkinson Disease and Ongoing Assessments

What are the cardinal features of Parkinson disease? What other motor and nonmotor symptoms do patients experience? Dr Isaacson describes diagnostic criteria and assessment tools.

Stuart H. Isaacson

BRIEF REPORT

A Man Made Manic: Levodopa-Carbidopa-Induced Mania in Traumatic Brain Injury

Here, read the case of a man admitted to the hospital in a manic state 15 years after suffering a traumatic brain injury. He had received several diagnoses over the past 2 years, including different iterations of bipolar disorder. His mania resolved after levodopa-carbidopa, which had been prescribed for an unsubstantiated diagnosis of Parkinson disease, was discontinued.

Ibrahim M. Sablaban and Mauran Sivananthan

VIEWPOINTS

NIMH Drug Trials for Schizophrenia

In this Viewpoint article, Torrey et al call for the National Institute of Mental Health to expand funding for schizophrenia treatment beyond trials that focus on identified biological targets. Specifically, they argue for treatment initiatives directed at normalizing the immune system.

E. Fuller Torrey & more

VIEWPOINTS

NIMH Supports Evidence-Based Treatments for Schizophrenia: A Response to Torrey et al

In this Viewpoint article, Dr Joshua Gordon, Director of the NIMH, responds to points raised by Torrey et al regarding the decrease in the number of medication trials for schizophrenia and the funding criteria used by the NIMH for such trials.

Joshua A. Gordon

ORIGINAL RESEARCH

Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs

Poor treatment adherence masks the true extent of placebo effects in trials of antipsychotics in schizophrenia. Can use of an injectable placebo in double-blind trials of long-acting injectable antipsychotics circumvent issues of adherence and provide a clearer picture of placebo effects? Read this article to find out.

Fumiaki Kumagai & more

EFFECTIVE MANAGEMENT APPROACHES FOR PSYCHOSIS IN PATIENTS WITH PARKINSON DISEASE

Effective Management Approaches for Psychosis in Patients With Parkinson Disease

Are you familiar with diagnostic criteria for Parkinson disease psychosis (PDP)? Do you know which psychotic symptoms occur in the majority of patients with PD? Read this CME supplement by 2 experts in the field for an update on PDP symptoms and treatments.

Rajesh Pahwa and Daniel E. Kremens

LETTERS TO THE EDITOR

Prevention of Dopamine Dysregulation Syndrome in Parkinson’s Disease: A Case Report

Dopamine dysregulation syndrome (DDS) is a rare complication in patients with Parkinson's disease. Patients with DDS typically take more than the recommended dose of dopamine replacement therapy and subsequently develop hallucinations and impulse control disorders. This report presents the case of an elderly man with Parkinson's disease and DDS who developed psychotic and hypersexual behaviors.

Walter T. Luchsinger & more

ORIGINAL RESEARCH

Prevalence of Impulsive-Compulsive Symptoms in Elderly Parkinson’s Disease Patients: A Case-Control Study

Impulse-control disorders (ICDs) have been noted anecdotally in patients with Parkinson's disease, but what is their true prevalence? To estimate this prevalence, this study compared the frequency of ICDs in elderly Parkinson's disease patients and healthy controls.

Maria Rita Lo Monaco & more

ORIGINAL RESEARCH

Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia

Aripiprazole lauroxil, a long-acting injectable antipsychotic, demonstrated safety and efficacy in treating schizophrenia symptoms in a recent RCT. But how does it stack up against other antipsychotics in terms of metabolic profile? Nasrallah and colleagues investigated this question as part of a phase 3 study in schizophrenia patients who were experiencing an acute relapse.

Henry A. Nasrallah & more

ORIGINAL RESEARCH

A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia

Herbert Y. Meltzer & more

Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1: Psychopharmacology and Neurobiological Effects

In addition to altering one’s perception of reality, psychedelics may be useful for trea...

Avinash Hosanagar & more

JCP JOURNAL-BASED CME - ORIGINAL RESEARCH

Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder and Retention in Outpatient Substance Use Disorder Treatment: A Retrospective Cohort Study

How does comorbid attention-deficit/hyperactivity disorder (ADHD) affect individuals with ...

Kristopher A. Kast & more

ASCP CORNER

Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2: Review of the Evidence

Could psychedelics such as psilocybin and LSD be useful in treating MDD or other psychiatr...

Avinash Hosanagar & more

Parkinson Disease

Sign-up to stay up-to-date today!

Already registered? Sign In

Sign-up to stay
up-to-date today!